WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine t…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Boryung Pharmaceutical Co., Ltd • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
New hope for rare blood cancer: lenalidomide dose study completed
Disease control CompletedThis study looked at the drug lenalidomide in 17 people with Waldenstrom macroglobulinemia, a rare blood cancer that had returned or stopped responding to other treatments. The main goal was to find a dose that is safe and tolerable. Researchers measured side effects and how many…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Lille • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New pill shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis study tested an experimental pill called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Cancer drug shows promise in rare blood cancer trial
Disease control CompletedThis study tested the drug carfilzomib in 7 people with Waldenström's macroglobulinemia, a rare blood cancer, that had returned after previous treatment. The goal was to see if the drug could shrink tumors and control the disease. Carfilzomib works by blocking a protein that canc…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New hope for lymphoma patients who can't handle standard drugs
Disease control CompletedThis study looked at a drug called zanubrutinib for people with certain types of B-cell lymphoma (like chronic lymphocytic leukemia or mantle cell lymphoma) who had to stop taking similar drugs (ibrutinib or acalabrutinib) because of bad side effects. The main goal was to see if …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Vaccine check: how well do COVID shots protect blood cancer patients?
Knowledge-focused CompletedThis study looked at whether the COVID-19 vaccine triggers a strong immune response in people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose in 146 participants. The goal was to understand vaccin…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated May 17, 2026 02:07 UTC
-
Needle-Free hope: urine and blood tests may spot rare blood cancer mutations
Knowledge-focused CompletedThis study looked at 300 people with Waldenström's macroglobulinemia or a related early condition. Researchers checked if genetic mutations found in bone marrow could also be detected in blood or urine samples. The goal was to see if these simpler, less painful tests could reliab…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated May 12, 2026 13:40 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC